We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
93 hedge funds and large institutions have $823M invested in Lyell Immunopharma in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
127% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 15
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
24% more funds holding
Funds holding: 75 → 93 (+18)
20% more capital invested
Capital invested by funds: $689M → $823M (+$135M)
0.12% more ownership
Funds ownership: 2.15% → 2.27% (+0.12%)
Holders
93
Holders Change
+18
Holders Change %
+24%
% of All Funds
1.6%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
22
Increased
34
Reduced
15
Closed
4
Calls
$15K
Puts
–
Net Calls
+$15K
Net Calls Change
-$3.86M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$18.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12M |
| 3 |
BlackRock
New York
|
+$11.7M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.27M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.65M |
